Graneto Matthew J, Kurumbail Ravi G, Vazquez Michael L, Shieh Huey-Sheng, Pawlitz Jennifer L, Williams Jennifer M, Stallings William C, Geng Lifeng, Naraian Ashok S, Koszyk Francis J, Stealey Michael A, Xu Xiangdong D, Weier Richard M, Hanson Gunnar J, Mourey Robert J, Compton Robert P, Mnich Stephen J, Anderson Gary D, Monahan Joseph B, Devraj Rajesh
Pfizer Global Research & Development, St. Louis Laboratories, 700 Chesterfield Village Parkway, Chesterfield, Missouri 63107, USA.
J Med Chem. 2007 Nov 15;50(23):5712-9. doi: 10.1021/jm0611915. Epub 2007 Oct 19.
A series of pyrazole inhibitors of p38 mitogen-activated protein (MAP) kinase were designed using a binding model based on the crystal structure of 1 (SC-102) bound to p38 enzyme. New chemistry using dithietanes was developed to assemble nitrogen-linked substituents at the 5-position of pyrazoles. Calculated log D was used in tandem with structure-based design to guide medicinal chemistry strategy and improve the in vivo activity of a series of molecules. The crystal structure of an optimized inhibitor, 4 (SC-806), in complex with p38 enzyme was obtained to confirm the hypothesis that the addition of a basic nitrogen to the molecule induces an interaction with Asp112 of p38 alpha. A compound identified from this series was efficacious in an animal model of rheumatic disease.
基于与p38酶结合的1(SC - 102)的晶体结构构建结合模型,设计了一系列p38丝裂原活化蛋白(MAP)激酶的吡唑类抑制剂。开发了使用二硫杂环丁烷的新化学方法,以在吡唑的5位组装氮连接的取代基。计算得到的log D与基于结构的设计一起用于指导药物化学策略,并提高一系列分子的体内活性。获得了优化抑制剂4(SC - 806)与p38酶复合物的晶体结构,以证实向分子中添加碱性氮会诱导与p38α的Asp112相互作用这一假设。从该系列中鉴定出的一种化合物在风湿性疾病动物模型中有效。